Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134857 | 0.79 | SLC6A2 (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4146672 | 0.63 | FGFR1 (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL4147272 | 0.62 | FGFR1 (0.40) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL31023685 | 0.61 | TDP1 (0.44) | SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL4146681 | 0.59 | SLC6A2 (0.41) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL8246543 | 0.59 | FGFR1 (0.37) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL20789939 | 0.59 | GABRP (0.40) | MEN1KMT2A | |
| SCHEMBL31023843 | 0.58 | ALDH1A1 (0.40) | SLC6A2SLC6A4HTR2ATDP1MEN1 | |
| SCHEMBL5996324 | 0.58 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL23360607 | 0.57 | HPGDS (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE4B | FGFR3 2047/4885KDR 1042/4885FGFR1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.